Novartis reveals five-year efficacy data for Kesimpta
Patients treated with Kesimpta experienced considerable decreases in relapse rates
Read More
Tag: Kesimpta
Novartis’ Kesimpta trial provides positive results for MS patients
MS patients given boost by results of study into Kesimpta – a self-administered treatment with potential to improve lives
Read More
Tecentriq, Kesimpta lead latest SMC decisions
SMC was unable to accept Pfizer’s Vyndaqel for use in patients with transthyretin amyloidosis
Read More
Novartis reveals long-term results for MS therapy Kesimpta
B-cell targeting therapy preserved patients’ IgG/IgM levels, with no increased risk of serious infections
Read More
Novartis’ MS therapy Kesimpta wins NICE backing
First self-administered, targeted B-cell therapy licensed for adults with relapsing forms of MS
Read More
Novartis bags EU, UK licences for MS therapy Kesimpta
Kesimpta is the first self-administered B-cell therapy for patients with relapsing forms of multiple sclerosis
Read More
Kesimpta and Vazkepa among latest CHMP recommendations
Bumper meeting saw 13 new medicines recommended for approval
Read More
Novartis’ melanoma combo fails in PhIII
The study assessed investigational immunotherapy spartalizumab (PDR001) in combination with targeted therapies Tafinlar and Mekinist
Read More
- HSE approves new treatment for hidradenitis suppurativa and axial spondyloarthritis
- MSD to acquire Cidara after positive phase 2b trial results
- eXmoor Pharma and Royal Free London link to strengthen UK gene therapy
- Alzheimer’s prevention charity pioneers research on nutrition biomarkers to detect risk
- NICE recommends vutrisiran for adults with ATTR-CM in final draft guidance
